AMGEN Inc

AMGNNASDAQ · USD
457.93USD0.00 (-0.95%)
6910

AMGEN Inc (AMGN) Implied Volatility Current

AMGN's 30 day implied volatility is 29.90%, with an IV Rank of 57.74%. This is an average IV Rank versus the past year, meaning AMGEN Inc options are fairly priced and currently offer no clear edge to buyers or sellers. AMGN's 30 day historical volatility sits at 26.80%, which means implied volatility is running 3.10 points above historical volatility, as of Nov 17, 2026.

Read more

Tracking AMGN implied volatility helps you spot when AMGEN Inc options are historically cheap or expensive, and where the best trades are hiding. When AMGN IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor AMGN implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking AMGN IV rank helps you see whether AMGN's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Implied Volatility

IV Rank
57.74%IV Rank
Moderate

IV is slightly elevated. Premiums are richer, leaning toward sellers.

Implied Volatility (30d)29.90%

IV Rank57.74%

Historical Volatility (30d)26.80%

IV Minus HV+3.10%

As of Nov 17, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →